Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2024-04-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
美康生物科技股份有限公司2023年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 85% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the year 2023, including amounts, relationships, accounting subjects, and reasons. It is a financial summary related to internal fund movements and related party transactions, approved by the board on April 17, 2024. The document length is 3941 characters, which is relatively short and does not contain comprehensive financial statements or management discussion. It is not an annual report, interim report, earnings release, or audit report. It is also not a regulatory filing or announcement of a report publication. The content is specific to related party transactions and fund occupation, which typically falls under regulatory disclosures or compliance filings. Given the nature and length, and absence of broader financial data or narrative, this document best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2024-04-18 Chinese
关于举行2023年度网上业绩说明会及征集相关问题的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's 2023 annual performance online briefing session (业绩说明会), scheduled for May 10, 2024. It references the 2023 annual report having been approved and published on the official disclosure website on April 19, 2024, but does not contain the report itself or detailed financial data. The document invites investors to participate in the online performance explanation meeting and to submit questions in advance. The document length is short (999 characters) and serves as a notice for an upcoming event related to the annual report, not the report itself. Therefore, it fits the category of an Investor Presentation announcement or a notice about a performance briefing. Given the options, the best fit is Investor Presentation (IP), as it is about a detailed presentation for investors focusing on financials and company performance, even though the actual presentation will occur later. It is not a full Annual Report (10-K), nor a Report Publication Announcement (RPA) because it does not announce the report's release but rather the briefing event. Confidence is high due to clear references and document purpose.
2024-04-18 Chinese
2023年度独立董事述职报告（李成艾）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance, opinions, committee work, investigations, communications with auditors, and other governance-related activities during the year 2023. The content focuses on the independent director's role, oversight, and governance activities rather than financial results or earnings. It includes detailed descriptions of board meetings, committee meetings, opinions on various corporate matters, and compliance with laws and regulations. This type of document is a management or board-related report focusing on governance and director duties rather than a financial report or announcement. It is not an Annual Report (10-K), Audit Report (AR), or Earnings Release (ER). It is not a Proxy Statement or Voting Results announcement. It is not a regulatory filing or announcement of a report publication. The document fits best under Board/Management Information (MANG) as it is a report by a board member about their management and governance activities during the year.
2024-04-18 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司2023年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a '2023年度持续督导跟踪报告' (2023 Annual Continuous Supervision Follow-up Report) issued by a sponsoring institution (中天国富证券有限公司) regarding 美康生物科技股份有限公司. It details the sponsor's review and supervision activities, including information disclosure, internal controls, fundraising supervision, governance, and regulatory compliance. The document includes summaries of work done, issues found, measures taken, and compliance with commitments. It is not a full annual report or financial statement but a regulatory supervision and follow-up report related to the sponsor's duties. The document length is 3185 characters, relatively short and focused on supervision activities rather than financial results or management discussion. This type of document fits best under Regulatory Filings (RNS), as it is a compliance and supervisory report rather than a financial report or announcement of voting results, management changes, or capital updates.
2024-04-18 Chinese
2023年年度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (517 characters) from Meikang Biotechnology Co., Ltd. It states that the company's 2023 Annual Report and its summary have been approved and will be disclosed on April 19, 2024, on the official disclosure website. The text does not contain the actual annual report or financial data but rather informs investors about the upcoming publication of the full report. According to the 'Menu vs Meal' rule, such a brief notice announcing the availability of a report is classified as a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2024-04-18 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Meikang Biotechnology Co., Ltd. It details the approval of various reports and proposals related to the company's 2023 annual activities, including the 2023 Annual Report, financial statements, profit distribution plan, internal control self-assessment report, and fundraising usage report. However, the document itself does not contain the full reports or detailed financial data; instead, it references that the full contents are published separately on the China Securities Regulatory Commission's designated disclosure website. The document is relatively short (3092 characters) and serves as an official announcement of the Supervisory Board's meeting resolutions and approvals, not the reports themselves. Therefore, according to the "Menu vs Meal" rule, this document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of meeting resolutions and approvals related to annual reports and other documents, but does not contain the full reports or substantive financial data itself.
2024-04-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.